Teramoto, K., Sengelov, M., West, E., Santos, M., Nadruz, W., Skali, H., and Shah, A. M. (2020) Association of pulmonary hypertension and right ventricular function with exercise capacity in heart failure. ESC Heart Failure, 7: 1635--1644. 10.1002/ehf2.12717.

Introduction {#ehf212717-sec-0004}
============

Both pulmonary hypertension (PH) and right ventricular (RV) dysfunction predict worse functional capacity and ventilatory efficiency and worse clinical outcomes in heart failure (HF) patients.[^1^](#ehf212717-bib-0001){ref-type="ref"} PH is observed in 40--75%[^2^](#ehf212717-bib-0002){ref-type="ref"}, [^3^](#ehf212717-bib-0003){ref-type="ref"} of patients with HF with reduced ejection fraction (HFrEF) and 30--80%[^4^](#ehf212717-bib-0004){ref-type="ref"}, [^5^](#ehf212717-bib-0005){ref-type="ref"} of those with HF with preserved ejection fraction (HFpEF), while RV dysfunction has been reported in 60% of HFrEF and up to 50% of HFpEF patients.[^6^](#ehf212717-bib-0006){ref-type="ref"} PH in HF primarily occurs secondary to left atrial hypertension. RV dysfunction in this context is thought to be secondary to elevated RV afterload, although existing studies also suggest a primary contractile abnormality of the RV itself.[^7^](#ehf212717-bib-0007){ref-type="ref"} Limited data are available regarding the association of PH and RV dysfunction with functional capacity and ventilatory efficiency independent of the degree of left heart dysfunction and left atrial hypertension and the extent to which these associations vary by left ventricular ejection fraction \[LVEF\]‐based HF phenotype.

We studied the association of pulmonary artery systolic pressure (PASP), RV function \[RV fractional area change (FAC)\], and the RVFAC/PASP ratio with functional capacity (percent predicted peak oxygen consumption \[VO~2~\]) and respiratory efficiency \[minute ventilation to carbon dioxide production ratio (V~E~/V~CO2~ slope)\] in 532 HF patients with a broad range of LVEF referred for cardiopulmonary exercise testing (CPET) and echocardiography. We hypothesized that higher pulmonary pressure and worse RV function at rest would predict worse functional capacity and ventilatory efficiency independent of LV systolic and diastolic function and that these associations will be similar among HF patients with preserved and impaired LVEF.

Methods {#ehf212717-sec-0005}
=======

Study population {#ehf212717-sec-0006}
----------------

Details of the study population have been previously described.[^8^](#ehf212717-bib-0008){ref-type="ref"} Of 975 consecutive patients referred for clinically indicated CPET for an indication of HF or cardiomyopathy between July 2007 and December 2014 at the Brigham and Women\'s Hospital, 137 did not undergo echocardiography and were excluded, another 290 patients were excluded because of inadequate tricuspid regurgitation (TR) and/or RV assessments, and an additional 16 patients were excluded because of missing data on clinical outcomes. This analysis therefore included 532 patients. This study was approved by the Partners Human Research Committee, who waived requirement for informed consent.

Definition of clinical variables and data collection {#ehf212717-sec-0007}
----------------------------------------------------

Clinical covariates including demographics, co‐morbidities, and medication usage were identified at the time of exercise testing. New York Heart Association (NYHA) functional class and values for serum haemoglobin and creatinine closest in time to the CPET date were extracted from chart review.

Cardiopulmonary exercise testing {#ehf212717-sec-0008}
--------------------------------

All CPET studies were performed at the Brigham and Women\'s Hospital exercise testing laboratory as previously described.[^9^](#ehf212717-bib-0009){ref-type="ref"} All patients underwent symptom‐limited CPET breathing room‐air with minute ventilation (V~E~), oxygen consumption (VO~2~), and carbon dioxide production (V~CO2~) measurements averaged over a 10 second‐interval. Peak VO~2~ was defined as the highest 10 second averaged VO~2~ during the last stage of the exercise test. Percent predicted peak VO~2~ was calculated using the Wasserman formula.[^10^](#ehf212717-bib-0010){ref-type="ref"} Minute ventilation to carbon dioxide production ratio (V~E~/V~CO2~) was recorded from rest to peak exercise. Age‐predicted maximal heart rate was estimated by Astrand\'s formula.[^11^](#ehf212717-bib-0011){ref-type="ref"}

Conventional echocardiography {#ehf212717-sec-0009}
-----------------------------

All quantitative measurements were performed by a single trained analyst in accordance with American Society of Echocardiography guidelines[^12^](#ehf212717-bib-0012){ref-type="ref"} and blinded to clinical information. Pulmonary arterial systolic pressure was calculated as PASP = 4 \* (peak TR velocity)². RV end‐diastolic area (RVEDA) and end‐systolic area (RVESA) were measured in the apical four‐chamber view focused on RV, and RVFAC was calculated as ((RVEDA − RVESA)/RVEDA) \* 100. Mitral regurgitation (MR) severity was assessed as the MR jet area‐to‐left atrial area ratio.

Ascertainment of clinical outcomes {#ehf212717-sec-0010}
----------------------------------

All‐cause mortality was ascertained through the National Death Index. Left ventricular assist device (LVAD) implantation and heart transplantation were ascertained through chart review. Occurrence of death, LVAD implantation, and heart transplantation were assessed through 31 December 2014 (median follow‐up 3.8 years). HF hospitalization was ascertained through 2 years after the CPET date by chart review and adjudication as previously described.[^9^](#ehf212717-bib-0009){ref-type="ref"}

Statistical analysis {#ehf212717-sec-0011}
--------------------

Clinical characteristics, cardiac structure and function, and exercise capacity were described by quartiles of PASP and of RVFAC. Unadjusted tests for trend across quartiles were performed, in addition to trend tests with the following adjustments: (1) demographics (age, sex, and race); (2) demographics and relevant co‐morbidities (coronary artery disease \[CAD\], hypertension, diabetes, atrial fibrillation, and chronic kidney disease \[CKD\]); and (3) demographics, co‐morbidities, and LVEF. Adjusting covariates were selected based on a priori knowledge.

The continuous associations of PASP, RVFAC, and RVFAC/PASP ratio with percent predicted peak VO~2~ and V~E~/V~CO2~ slope were assessed using multivariable linear regression. Possible non‐linear associations were assessed using restricted cubic splines modelled. For analyses with PASP as primary predictor variable, linear regression and cubic spline models were adjusted for demographics and co‐morbidities, LVEF, presence of moderate or greater MR, and left atrial volume index (LAVI). Analyses with RVFAC as the primary predictor employed the same adjustment covariates, except that PASP was included while LAVI and moderate or greater MR were not included as adjustment variables as elevations in left atrial pressure are expected to impact RV function primarily through associated elevations in pulmonary artery pressure. The association of PASP and RVFAC with incident events was assessed using multivariable Cox proportional hazard models with the same adjustment variables. The proportional hazards assumption was tested based on the Schoenfeld residuals, and no violation was detected. All analyses were also performed stratified by LVEF (≥45% vs. \<45%), with tests for interaction performed using multiplicative interaction terms.

All statistical analyses were performed using Stata software version 15.0 (Stata Corp LP, College Station, TX, USA). Two‐sided *P* value of \<0.05 was considered statistically significant.

Results {#ehf212717-sec-0012}
=======

Among the 532 patients included in this analysis, mean age was 55.9 ± 14.0 years, 66% were male patients, 84% were white, and the mean LVEF was 35 ± 15% (*Table* [*1*](#ehf212717-tbl-0001){ref-type="table"}). The median PASP was 29 mmHg (25th to 75th percentile range 23 to 38 mmHg), and the median RVFAC was 42% (31% to 52%). When compared with patients not included in this analysis, those included were older, less likely to be obese, had higher prevalence of atrial fibrillation and CKD, and higher NYHA class, but had similar peak VO~2~ (*Table* [*S1*](#ehf212717-supitem-0001){ref-type="supplementary-material"}).

###### 

Baseline Characteristics for PASP quartiles

                                                             PASP Quartile                 ANOVA *p*‐values                                                  
  -------------------------------------- ----- ------------- --------------- ------------- ------------------ ------------- ---------- ---------- ---------- ----------
  **Clinical background**                                                                                                                                    
  **Demographic**                                                                                                                                            
  Age, year, mean                        532   55.9 ± 14.0   51.3 ± 13.7     55.3 ± 14.3   58.2 ± 14.3        58.9 ± 12.6   \< 0.001   ‐          ‐          ‐
  Male, (%)                              532   350 (66%)     80 (60%)        87 (66%)      82 (60%)           101 (77%)     0.013      ‐          ‐          ‐
  White, (%)                             532   444 (84%)     113 (84%)       109 (83%)     116 (85%)          106 (81%)     0.580      ‐          ‐          ‐
  BMI, kg/m^2^                           532   27.7 ± 0.2    27.4 ± 5.4      28.1 ± 5.9    27.6 ± 5.6         27.7 ± 5.5    0.820      0.67       ‐          ‐
  NYHA III & IV, (%)                     532   206 (39%)     36 (27%)        40 (31%)      60 (44%)           70 (53%)      \< 0.001   \< 0.001   ‐          ‐
  Ischemic cardiomyopathy, (%)           532   132 (25%)     21 (16%)        27 (20%)      35 (27%)           49 (37%)      \< 0.001   0.047      ‐          ‐
  **Co‐morbidities**                                                                                                                                         
  Hypertension, (%)                      532   313 (59%)     62 (46%)        71 (54%)      88 (65%)           92 (70%)      \< 0.001   0.07       ‐          ‐
  Diabetes, (%)                          532   138 (26%)     17 (13%)        28 (21%)      43 (32%)           50 (38%)      \< 0.001   0.001      ‐          ‐
  CAD, (%)                               532   196 (37%)     30 (22%)        42 (32%)      54 (40%)           70 (53%)      \< 0.001   0.004      ‐          ‐
  Afib, (%)                              532   191 (36%)     35 (26%)        43 (33%)      58 (43%)           55 (42%)      0.002      0.29       ‐          ‐
  CKD, (%)                               532   170 (32%)     24 (18%)        36 (28%)      52 (38%)           58 (44%)      \< 0.001   0.01       ‐          ‐
  COPD, (%)                              532   52 (10%)      4 (3%)          9 (7%)        21 (15%)           18 (14%)      \< 0.001   0.026      ‐          ‐
  Anaemia, (%)                           532   150 (28%)     24 (18%)        33 (25%)      42 (31%)           51 (39%)      \< 0.001   0.014      ‐          ‐
  **Echocardiographic parameters**                                                                                                                           
  **Cardiac structure**                                                                                                                                      
  MWT, cm                                531   0.98 ± 0.23   0.93 ± 0.20     0.99 ± 0.21   1.00 ± 0.23        0.99 ± 0.26   0.034      0.4        0.39       0.27
  LVEDVI, ml/m^2^                        532   92 ± 41       82 ± 34         85 ± 37       94 ± 36            107 ± 51      \< 0.001   \< 0.001   0.07       0.65
  LVMi, g/m^2^                           531   117 ± 39      108 ± 41        111 ± 38      122 ± 40           125 ± 37      \< 0.001   0.005      0.76       0.69
  **LV Function**                                                                                                                                            
  LVEF, %                                532   35 ± 15       39 ± 13         38 ± 14       33 ± 15            29 ± 15       \< 0.001   \< 0.001   ‐          ‐
  e\' septal, cm/sec                     428   6.1 ± 2.4     6.7 ± 2.6       6.6 ± 2.4     5.6 ± 2.1          5.4 ± 2.0     \< 0.001   0.006      0.41       0.36
  E/e\' septal                           428   16 ± 9        12 ± 5          12 ± 7        19 ± 9             21 ± 10       \< 0.001   \< 0.001   \< 0.001   \< 0.001
  LAVi, ml/m^2^                          532   39 ± 18       30 ± 14         34 ± 15       43 ± 19            49 ± 19       \< 0.001   \< 0.001   \< 0.001   ‐
  MR severity mod‐severe, %              532   179 (33.6%)   34 (25.4%)      36 (27.1%)    55 (41.7%)         54 (40.6%)    \< 0.001   0.003      0.4        ‐
  **RV Hemodynamics**                                                                                                                                        
  RVFAC, %                               532   41 ± 13       45 ± 13         45 ± 13       40 ± 13            35 ± 12       \< 0.001   \< 0.001   \< 0.001   0.003
  TR velocity, m/s                       532   2.5 ± 0.6     1.7 ± 0.4       2.3 ± 0.1     2.7 ± 0.1          3.2 ± 0.3     \< 0.001   \< 0.001   \< 0.001   \< 0.001
  PVR, WU                                443   2.3 ± 1.3     1.5 ± 0.6       1.9 ± 0.9     2.7 ± 1.3          33 ± 1.4      \< 0.001   \< 0.001   \< 0.001   \< 0.001
  **Cardiopulmonary exercise testing**                                                                                                                       
  Peak RER                               532   1.2 ± 0.1     1.2 ± 0.1       1.2 ± 0.1     1.2 ± 0.1          1.2 ± 0.1     0.69       0.86       0.93       0.87
  Resting HR, bpm                        532   73 ± 14       71 ± 14         71 ± 15       74 ± 14            75 ± 13       0.003      0.001      0.25       0.73
  Peak HR, bpm                           532   122 ± 29      129 ± 32        128 ± 28      118 ± 27           113 ± 25      \< 0.001   \< 0.001   0.11       0.1
  Resting SBP, mmHg                      532   116 ± 20      114 ± 17        118 ± 20      116 ± 19           115 ± 22      0.74       0.31       0.48       0.47
  Peak SBP, mmHg                         529   137 ± 29      141 ± 29        146 ± 29      133 ± 28           130 ± 27      \< 0.001   \< 0.001   0.012      0.028
  SBP reserve, mmHg                      529   22 ± 21       27 ± 22         29 ± 20       17 ± 20            15 ± 19       \< 0.001   \< 0.001   0.001      0.007
  Resting DBP, mmHg                      532   73 ± 11       72 ± 10         75 ± 10       74 ± 12            72 ± 11       0.47       0.07       0.09       0.07
  Peak DBP, mmHg                         526   74 ± 12       73 ± 12         76 ± 11       74 ± 11            71.8 ± 11.5   0.1        0.028      0.07       0.07

Demographic; age, sex, and race

Co‐morbidities; coronary artery disease, hypertension, diabetes, chronic kidney disease, atrial fibrillation

PASP, pulmonary arterial systolic pressure; ANOVA, Analysis of variance; BMI, body mass index; NYHA, New York Heart Association classification; CAD, coronary artery disease; Afib, atrial fibrillation; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; MWT, mean wall thickness; LVEDVI, left ventricular end‐ diastolic volume index; LVMi, left ventricular mass index; LVEF, left ventricular ejection fraction; LAVi, left atrial volume index; MR, mitral regurgitation; RVFAC, right ventricular fractional area change; TR, tricuspid regurgitation; PVR, pulmonary vascular resistance; RER, respiratory exchange ratio; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure

Higher PASP was associated with older age, male sex, and a higher prevalence of cardiovascular risk factors (hypertension, diabetes, and CKD) and CAD (*Table* [*1*](#ehf212717-tbl-0001){ref-type="table"}). Similarly, lower RVFAC was associated with male sex, CAD, CKD, and was also robustly associated with atrial fibrillation ([*Table S2*](#ehf212717-supitem-0001){ref-type="supplementary-material"}). In contrast to PASP, RVFAC was not associated with age or hypertension. Both higher PASP and lower RVFAC were associated with worse NYHA functional class.

Association of PASP and RVFAC with left heart structure and function {#ehf212717-sec-0013}
--------------------------------------------------------------------

In models adjusted for patient demographics, higher PASP was associated with lower LVEF, larger LV volume, higher LV mass index, worse diastolic indices (lower TDI e′, higher E/e′, larger LAVI), worse MR, and worse RVFAC. After further adjustment for LVEF, only associations with higher LV filling pressure (E/e′, LA volume index) and worse RVFAC persisted.

Similar to PASP, worse RVFAC was associated with lower LVEF, larger LV volume, and higher LV mass index, worse diastolic indices (lower TDI e′, higher E/e′, and larger LA volume index), worse MR, and higher PASP in analyses adjusted for patient demographics ([*Table S2*](#ehf212717-supitem-0001){ref-type="supplementary-material"}). After further adjusting for LVEF, only associations with measures of higher LV filling pressure (E/e′, LAVi) and higher PASP persisted. When additionally accounting for PASP, worse RVFAC remained related to higher E/e′.

Association of PASP and RVFAC with functional capacity and ventilatory efficiency {#ehf212717-sec-0014}
---------------------------------------------------------------------------------

Exercise effort, as reflected in the peak exercise respiratory exchange ratio, did not vary across PASP or RVFAC quartiles (*Table* [*1*](#ehf212717-tbl-0001){ref-type="table"} and [*Table S2*](#ehf212717-supitem-0001){ref-type="supplementary-material"}). After accounting for demographics and LVEF, higher resting PASP was associated with lower peak exercise systolic blood pressure and lower systolic blood pressure reserve. Worse resting state RVFAC correlated with a higher resting heart rate in addition to lower peak exercise systolic blood pressure and lower systolic blood pressure reserve.

Higher PASP was linearly associated with lower percent predicted peak VO~2~ (*Figure* [*1*](#ehf212717-fig-0001){ref-type="fig"}, *Table* [*2*](#ehf212717-tbl-0002){ref-type="table"}). In models adjusted for age, sex, race, hypertension, diabetes, CAD, CKD, LVEF, the presence of moderate or greater MR, and LAVi, each 5 mmHg increase in PASP was associated with 1% point decrease in ppVO~2~. In adjusted analysis, higher PASP was not significantly associated with V~E~/V~CO2~ slope. Lower RVFAC was also linearly associated with lower percent predicted peak VO~2~ in adjusted analysis, with each 5% decrease in RVFAC was associated with 1% point decrease in ppVO~2~ (*Figure* [*2*](#ehf212717-fig-0002){ref-type="fig"}, *Table* [*2*](#ehf212717-tbl-0002){ref-type="table"}). Worse RVFAC also predicted worse exercise ventilatory inefficiency, with each 5% decrease in RVFAC associated with a 0.67‐point increase in V~E~/V~CO2~ slope in adjusted analysis (*Figure* [*2*](#ehf212717-fig-0002){ref-type="fig"}, *Table* [*3*](#ehf212717-tbl-0003){ref-type="table"}). Lower RVFAC/PASP ratio, a measure of RV‐to‐PA coupling, demonstrated significant non‐linear associations with both worse ppVO~2~ and higher V~E~/V~CO2~ slope (*Figure* [*3*](#ehf212717-fig-0003){ref-type="fig"}). Importantly, the relationships between RVFAC/PASP ratio and each measure were most robust within the range of values observed in the majority of study subjects (*Figure* [*3*](#ehf212717-fig-0003){ref-type="fig"}, histogram).

![-- Association between PASP and *(A)* percent predicted peak VO~2~, *(B)* V~E~/V~CO2~ slope stratified by LVEF phenotype. β‐coefficients are presented by per 5 mmHg increase in PASP.\
Both adjusted for age, sex, race, CAD, HT, DM, AF, CKD, LVEF, MR severity, and LAVi.](EHF2-7-1635-g001){#ehf212717-fig-0001}

###### 

Continuous association of pulmonary pressure and RV function vs. exercise capacity

                               Percent predicted peak VO~2~   V~E~/V~CO2~ slope                                                                                                                                                                                                           
  ---------------------------- ------------------------------ ---------------------------------------------------- ---------------------------------------------------- ------------------------ --------------------- ---------- --------------------- ---------- ---------------------- -------
  PASP (per 5 mmHg increase)   532                            Non‐linear                                           \< 0.001[^‡^](#ehf212717-note-0008){ref-type="fn"}   −0.98 \[−1.63, −0.32\]   0.004                 530        0.15 \[0.07, 0.23\]   \< 0.001   0.40 \[−0.02, 0.82\]   0.064
  RVFAC (per 5% decrease)      Non‐linear                     \< 0.001[^‡^](#ehf212717-note-0008){ref-type="fn"}   −1.02 \[−1.69, −0.36\]                               0.002                    1.21 \[0.83, 1.59\]   \< 0.001   0.67 \[0.24, 1.09\]   0.002                             

Demographics; age, sex, and race

Additional measures

For PASP and RVFAC/PASP; CAD, HT, DM, AF, CKD, LVEF, MR severity, and LAVi

For RVFAC; CAD, HT, DM, AF, CKD, LVEF and PASP

Overall *p*‐value from cubic spline regression

![‐ Association between RVFAC and *(A)* percent predicted peak VO~2~, *(B)* V~E~/V~CO2~ slope stratified by LVEF phenotype. β‐coefficients are presented by per 5% increase in RVFAC. Both adjusted for age, sex, race, CAD, HT, DM, AF, CKD, LVEF, and PASP.](EHF2-7-1635-g002){#ehf212717-fig-0002}

###### 

Hazard ratio for composite event by PASP, RVFAC, and RVFAC/PASP

                                         **Composite event**  **Composite event + HF Admission**                                                                                                                                                                        
  ------------------------------------- --------------------- ------------------------------------ --------------------- ---------- --------------------- ---------- --------------------- --------------------- --------------------- ---------- --------------------- -------
  PASP (per 5 mmHg increase)                     167          8.1 \[7.0--9.5\]                     1.15 \[1.09--1.21\]   \< 0.001   1.07 \[1.00--1.14\]   0.029               165           25.8 \[22.1--30.0\]  1.13 \[1.07--1.19\]   \< 0.001   1.06 \[1.00--1.13\]   0.055
  RVFAC (per 5% decrease)                1.29 \[1.22--1.38\]  \< 0.001                             1.17 \[1.09--1.25\]   \< 0.001   1.25 \[1.17--1.33\]   \< 0.001    1.14 \[1.07--1.22\]        \< 0.001                                                               
  RVFAC/PASP (per 0.1%/mmHg decrease)    1.09 \[1.06--1.12\]  \< 0.001                             1.04 \[1.02--1.07\]   0.001      1.07 \[1.05--1.10\]   \< 0.001    1.04 \[1.01--1.06\]          0.002                                                                

Demographics; age, sex, and race

Composite event includes all‐cause death, heart transplant, and left ventricular assist device implantation.

Additional adjusting measures

For PASP and RVFAC/PASP; LVEF, MR severity, and LAVi

For RVFAC; LVEF and PASP

![-- Association between RVFAC/PASP and *(A)* percent predicted peak VO~2~, *(B)* V~E~/V~CO2~ slope stratified by LVEF phenotype. β‐coefficients are presented by per 5% increase in RVFAC. Both adjusted for age, sex, race, CAD, HT, DM, AF, CKD, and LVEF.](EHF2-7-1635-g003){#ehf212717-fig-0003}

Effect measure modification by baseline left ventricular ejection fraction {#ehf212717-sec-0015}
--------------------------------------------------------------------------

We observe significant effect modification of LVEF category on the relationship of PASP with percent predicted peak VO~2~ achieved (*Figure* [*1*](#ehf212717-fig-0001){ref-type="fig"}; interaction *P* = 0.006). For any given increase in PASP, the associated decline in percent predicted VO~2~ was greater among patients with LVEF ≥45% compared with those with LVEF \<45%. Baseline LVEF (≥45% or \<45%) did not significantly modify the relationship of PASP or RVFAC with V~E~/V~CO2~ slope or the relationship of RVFAC with percent predicted peak VO~2~ (*Figures* [*1*](#ehf212717-fig-0001){ref-type="fig"} and [*2*](#ehf212717-fig-0002){ref-type="fig"}). Similar results were observed in sensitivity analyses comparing patients with LVEF ≥50% with those with LVEF \<50% (*Figures* [*S1*](#ehf212717-supitem-0002){ref-type="supplementary-material"} and [*S2*](#ehf212717-supitem-0003){ref-type="supplementary-material"}).

Association of PASP and RVFAC with clinical outcomes {#ehf212717-sec-0016}
----------------------------------------------------

At a median follow‐up of 3.9 years (25th to 75th percentile range 0.05 to 7.38), 167 patients experienced the composite of death, LVAD implantation, or transplantation \[event rate 8.1 (95% CI 7.0--9.5) per 100 person years\]. Each 5 mmHg increase in PASP was associated with a 7% increase in the risk of this composite in models adjusted for age, sex, race, LVEF, moderate or greater MR, and LAVi (*P* = 0.03; *Table* [*3*](#ehf212717-tbl-0003){ref-type="table"}). Similarly, each 5% decrease in RVFAC was associated with 17% increased risk for composite event (*P* \< 0.001), and a 0.1 unit (%/mmHg) decrease in the RVFAC/PASP ratio was associated with a 4% increase in risk. These associations were not significantly non‐linear (online *Figure* [*S3*](#ehf212717-supitem-0003){ref-type="supplementary-material"}).

At 2 year follow‐up, the composite of death, LVAD implantation, transplantation or HF hospitalization occurred in 165 patients \[event rate 25.8 (95% CI 22.1--30.0) per 100 person years\]. The association of PASP with this composite endpoint was of borderline statistical significance (*Table* [*3*](#ehf212717-tbl-0003){ref-type="table"}). As opposed to PASP, each 5% decrease in RVFAC was associated with and 14% increase in risk, and each 0.1 unit (%/mmHg) decrease in RVFAC/PASP ratio was associated with a 4% increase in risk.

Discussion {#ehf212717-sec-0017}
==========

Higher pulmonary pressure and reduced RV function both predict incident HF and mortality in the community[^13^](#ehf212717-bib-0013){ref-type="ref"} and are associated with adverse prognosis in prevalent HF regardless of LVEF.[^5^](#ehf212717-bib-0005){ref-type="ref"}, [^14^](#ehf212717-bib-0014){ref-type="ref"}, [^15^](#ehf212717-bib-0015){ref-type="ref"}, [^16^](#ehf212717-bib-0016){ref-type="ref"} Pulmonary vascular dysfunction is of particular interest in the heterogeneous syndrome of HFpEF, as older patients with PH and RV dysfunction appear to represent a disease sub‐phenotype with particularly high risk of death and HF hospitalization.[^17^](#ehf212717-bib-0017){ref-type="ref"} This study assessed the contributions of PH and RV dysfunction to functional capacity and respiratory efficiency in HF, independent of LV structure and function. We report three main findings. First, higher pulmonary pressure at rest significantly predicted worse functional capacity (i.e. reduced ppVO~2~), and this relationship was stronger among HF patients with an LVEF ≥45% compared with those with LVEF \<45% (*P* ~interaction~ = 0.006). Second, worse RV function at rest---even when within the normal range---was associated with both worse functional capacity and worse respiratory efficiency (i.e. increased V~E~/V~CO2~ slope) and apparently more so among subjects with reduced LVEF. Furthermore, worse RV‐PA coupling (i.e. RVFAC/PASP ratio) at rest also predicted worse functional capacity and respiratory efficiency, supporting a primary role for RV dysfunction in limiting cardiopulmonary reserve in HF. Third, PASP, RVFAC, and RVFAC/PASP ratio were each associated with a higher risk of death, transplant, LVAD, and with the composite of these plus HF hospitalization independent of echocardiographic measures of LV function or filling pressure.

Left heart dysfunction with associated elevation in left atrial pressure is the most frequent aetiology of PH, which has a reported prevalence of 30--80% in HF depending on the ascertainment methods and definitions employed.[^2^](#ehf212717-bib-0002){ref-type="ref"}, [^5^](#ehf212717-bib-0005){ref-type="ref"}, [^18^](#ehf212717-bib-0018){ref-type="ref"} PH is common in HFpEF in particular, with a prevalence of 50% in referral population[^4^](#ehf212717-bib-0004){ref-type="ref"} and rising to up to 80% in some community‐based HFpEF samples.[^5^](#ehf212717-bib-0005){ref-type="ref"} Concordant with prior reports, we observed a heightened risk of cardiovascular morbidity and mortality associated with higher PASP irrespective of LVEF.[^3^](#ehf212717-bib-0003){ref-type="ref"} Higher resting PASP also predicted lower ppVO~2~ and higher V~E~/V~CO2~ slope. Higher rest pulmonary pressures may simply be a marker of more advanced LV dysfunction (systolic and diastolic). However, our finding of significant associations of rest PH with functional capacity, ventilatory efficiency, and clinical events after adjusting for measures of LV systolic function and diastolic function argues against PH as just a risk marker in HF. The association of higher resting PASP with worse functional capacity was stronger among those with LVEF ≥45% compared with those with LVEF \<45%. The reasons for this differential association are not clear but provide support for an important role of PH in HFpEF morbidity and mortality. Multiple ongoing Phase II trials of interventions targeting PH in HFpEF will provide insights into the impact of treating PH on functional capacity or hemodynamics in HFpEF.[^19^](#ehf212717-bib-0019){ref-type="ref"}

Right ventricular dysfunction has been reported in up to 65% of patients with HFrEF,[^20^](#ehf212717-bib-0020){ref-type="ref"} and anywhere from 4--49% of patients with HFpEF.[^16^](#ehf212717-bib-0016){ref-type="ref"}, [^18^](#ehf212717-bib-0018){ref-type="ref"}, [^21^](#ehf212717-bib-0021){ref-type="ref"} While some studies suggest an equivalent frequency in HFrEF and HFpEF,[^14^](#ehf212717-bib-0014){ref-type="ref"}, [^22^](#ehf212717-bib-0022){ref-type="ref"} others have observed a 1.5 to two‐fold higher prevalence in HFrEF.[^21^](#ehf212717-bib-0021){ref-type="ref"}, [^23^](#ehf212717-bib-0023){ref-type="ref"} Using an RVFAC \<35% to define RV dysfunction, as recommended by the American Society of Echocardiography,[^24^](#ehf212717-bib-0024){ref-type="ref"} we observed RV dysfunction in 15% of HF patients with LVEF ≥45% and 39% of those with LVEF \<45%. RV dysfunction is strongly associated with adverse outcomes in HF, including both mortality and recurrent HF hospitalization.[^25^](#ehf212717-bib-0025){ref-type="ref"} Among patients with HFrEF, RV dysfunction is associated with reduced exercise capacity. Chronic RV dysfunction may primarily limit stroke volume and may exaggerate reductions in stroke volume and cardiac output related to LV dysfunction through ventricular interdependence. Resting state RV dysfunction may thereby also limit SV and CO augmentation in response to excise, contributing to blunted functional capacity in HF.[^26^](#ehf212717-bib-0026){ref-type="ref"} Indeed, our findings show that resting‐state RV dysfunction predicts worse functional capacity independent of LV structure and function and in both HF with LVEF ≥45% and \<45%.

Right ventricular dysfunction in HF may occur via both "afterload‐dependent" (i.e. PH) and "afterload‐independent" pathways, with the later related to primary myocardial contractile abnormality. RV‐pulmonary artery coupling (RV‐PA coupling) assesses the ability of RV function to match RV afterload. While PH is common in HFpEF, a steeper PA pressure‐flow relationship has been described in HFpEF compared with HF‐free controls, consistent with lower RV‐PA coupling and worse intrinsic RV contractility.[^27^](#ehf212717-bib-0027){ref-type="ref"} We observed that worse RV‐PA coupling was also associated with lower functional capacity and greater respiratory inefficiency. Interestingly, this association was non‐linear, with the most robust associations noted at RVFAC/PASP \< \~2%/mmHg, values observed in majority of our cohort. This is consistent with a prior study in which worse RV‐PA coupling---assessed as the tricuspid annular plane systolic excursion/PASP ratio---was associated with worse functional capacity and respiratory efficiency.[^1^](#ehf212717-bib-0001){ref-type="ref"} These relationships were not differential based on LVEF in our study.

This study has several limitations. This study was a single centre, observational study of clinically referred patients for CPET and echocardiography, which may limit the generalizability of our findings to HF patients more broadly. PASP was estimated by echocardiography. Although previous studies have demonstrated good correlation between non‐invasively (Doppler echocardiography) obtained and invasively obtained pulmonary pressure,[^28^](#ehf212717-bib-0028){ref-type="ref"} this remains an estimate and may result in misclassification. RV function was assessed using RVFAC. Although a well‐validated and prognostic measure in HF, we did not have data on tricuspid annular plane systolic excursion, a commonly employed RV functional measure. We stratified LVEF at 45% based on contemporary therapeutic HFpEF trial,[^29^](#ehf212717-bib-0029){ref-type="ref"} although guideline recommendations for defining HFpEF specify an LVEF ≥50%.[^30^](#ehf212717-bib-0030){ref-type="ref"}

Among HF patients with a broad range of LVEF, greater resting‐state pulmonary pressure and worse RV function both independently predict worse functional capacity and greater respiratory inefficiency, independent of LV structure and function. The magnitude of association of pulmonary pressure with functional capacity was greater in HFpEF compared with HFrEF, while no statistically significant differences in the association of RV dysfunction with functional capacity were noted by LVEF. These findings support a role for pulmonary vascular and RV dysfunction in contributing to impaired exercise tolerance in HF regardless of LV function.
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**Figure S2**. ‐ Association between RVFAC and (A) percent predicted peak VO~2~, (B) V~E~/V~CO2~ slope stratified by LVEF phenotype (defined by LVEF cutoff point of 50%). β‐coefficients are presented by per 5% increase in RVFAC. Both adjusted for age, sex, race, CAD, HT, DM, AF, CKD, LVEF, and PASP.
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**Figure S3**. -- Associations between (A) PASP and (B) RVFAC with composite outcomes of death, transplant, or LVAD implantation. Incidence rates are presented per 100 person‐years.
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